Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Departments

Diabetes: Too Big and Too Bad to Ignore Any Longer

  1. Matthew C. Riddle, Reviewed by, MD
    Clinical Diabetes 2004 Apr; 22(2): 90-91. https://doi.org/10.2337/diaclin.22.2.90
    PreviousNext
    • Article
    • Info & Metrics
    • PDF
    Loading

    STUDY

    Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF: Lifetime risk for diabetes mellitus in the United States.

    JAMA 290:1884–1890, 2003
    OpenUrlCrossRefPubMedWeb of Science

    SUMMARY

    Objective. To estimate the lifetime risk of developing diabetes for people of various ages and the expected effects of diabetes on their life expectancy.

    Design and methods. Researchers developed a predictive model, the main dataset for which was derived from an ongoing cross-sectional survey of the U.S. population, which included 120,000 individuals in the year 2000, with additional information from earlier years. Information on mortality rates from U.S. Census Bureau records was also included, as well as diabetes-specific mortality rates from a smaller regional study. The resulting model was extended using a number of conservative assumptions to project the incidence of diabetes and its effects on mortality into the future.

    Results and conclusions. The findings were striking. The lifetime risk of developing diabetes for an individual born in the United States in 2000 was estimated to be 33% for men and 39% for women. Risk was lowest for the subpopulation identified as “white” (27% for men and 31% for women) and somewhat higher for those described as “black” and “other” (presumably those of Asian, Pacific Islander, or mixed ethnicity). The highest risk was found in the subgroup identified as “Hispanic” (45% for men and 53% for women). For people already 50 years old and not known to have diabetes, the predicted rates were still remarkably high: 26% risk of developing diabetes for men and 28% risk for women. At age 50 and older, the nonwhite population continued to have more risk than the others, and Hispanic women continued to have the highest risk: 44% likelihood of developing diabetes.

    The predicted increase of mortality rates after diagnosis of diabetes was also impressive. Children (either boys or girls) developing diabetes in 2000 at age 10 were predicted to live about 19 fewer years than they would have without diabetes. Assuming that diabetes reduces the quality as well as duration of life, the loss of quality-adjusted life years (QALYs) for such children was predicted to be 31 for boys and 33 for girls. When diagnosed with diabetes at age 50, men were predicted to lose about 9 years of life and 15 QALYs, and women were predicted to lose 12 years and 18 QALYs.

    The authors concluded that prevention of diabetes and prevention of its complications are important public health priorities.

    COMMENTARY

    This article by epidemiologists from the Centers for Disease Control and Prevention describes a simple yet powerful analysis with far-reaching implications. A commentary on its findings presents the challenge of where to start.

    The limitations of the findings should come first. Models depend on the quality of data and the accuracy of assumptions. The data here derived from a population-based effort that has been underway for more than a decade. However, the main data were collected by telephone survey, a method with obvious limitations.

    Concerning their assumptions in the model, the authors make a persuasive case that their analysis probably underestimates, rather than exaggerates, the present and future harm from diabetes. For example, they chose not to anticipate the continuing increase of obesity with its certain effects on diabetes. A repeat analysis in 2010 might predict even higher risks.

    Perhaps the weakest part of the model concerns quality of life, which is subjective and varies markedly among individuals. Although a 25% reduction in quality of life from diabetes may be a fair overall assumption, it fails to reflect the profound impairments (loss of vision, limbs, mobility, or mental function) that can result from various complications of diabetes in less-fortunate individuals. Moreover, further study (for example, of impairment of mental function)1 may add weight to the evidence that quality, as well as quantity, of life is reduced by diabetes.

    Accepting these unavoidable limitations of the model, however, its predictions remain staggering. They certainly refute the view that diabetes is an unimportant disorder with little significance for personal and national health planning. As the authors point out, breast cancer occurs in one of eight women and one of 16 of the entire population2 and receives outstanding and well-deserved media coverage and financial support. People literally march in the streets to confront this important problem. In contrast, diabetes is expected to occur in more than one in three people born in this country, yet it attracts much less interest. If diabetes were a trivial problem, its high incidence might not matter. But the second part of the analysis dispels this view. The most notable prediction in this article may be the projected loss of 9 years of life for men and 12 for women who learn they have diabetes at age 50, a typical age of diagnosis. This observation confirms and updates earlier studies,3 while relating the substantial loss of life-years to the very high lifetime risk of diabetes.

    Writings on health economics include efforts to define the monetary value of health and illness. Medical efforts can be rated according to the cost of preserving one QALY.4 Estimates range from $20,000 to $50,000 per QALY saved as an appropriate level of expense. Consider, then, the potential value of 18 QALYs expected to be lost by an average 50-year-old woman just diagnosed with diabetes. At $50,000 per QALY, that comes to $900,000. Much could be done to prevent or delay the onset of diabetes or its complications with less money than that.

    The authors were cautious in judging the significance of their findings, but a much more vigorous statement seems justified. If more than one in three people born in the United States will develop diabetes, and if each may lose a decade of life or more, why do we not have a clear public health policy for this disorder? Exhortation to eat less and exercise more has not worked in medical practice and will not work as public policy. These findings justify nationwide efforts to prevent diabetes and minimize its complications, notably by assuring that all people at risk (that is, everyone) have access to preventive and therapeutic health services.

    Footnotes

    • Matthew C. Riddle, MD, is a professor of medicine at Oregon Health & Science University in Portland, Ore.

    • American Diabetes Association

    References

    1. ↵
      Strachan MWJ, Deary IJ, Ewing FME, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20:438–445, 1997
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Feuer EJ, Wung L, Boring CC, Flanders WD, Timmel MJ, Tong T: The lifetime risk of developing breast cancer. J Natl Cancer Inst 85:892–897, 1993
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Gu K, Cowie CC, Harris MI: Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 21:1138–1145, 1998
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Laupacis A, Feeny D, Detsky AS, Tugwell TX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Ass J 146:473–481, 1992
      OpenUrlAbstract
    PreviousNext
    Back to top

    In this Issue

    April 2004, 22(2)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Clinical Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Diabetes: Too Big and Too Bad to Ignore Any Longer
    (Your Name) has forwarded a page to you from Clinical Diabetes
    (Your Name) thought you would like to see this page from the Clinical Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Diabetes: Too Big and Too Bad to Ignore Any Longer
    Matthew C. Riddle
    Clinical Diabetes Apr 2004, 22 (2) 90-91; DOI: 10.2337/diaclin.22.2.90

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Diabetes: Too Big and Too Bad to Ignore Any Longer
    Matthew C. Riddle
    Clinical Diabetes Apr 2004, 22 (2) 90-91; DOI: 10.2337/diaclin.22.2.90
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • STUDY
      • SUMMARY
      • COMMENTARY
      • Footnotes
      • References
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients
    • Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
    • Timely News and Notes for Primary Care Providers from the American Diabetes Association
    Show more Departments

    Similar Articles

    Navigate

    • Current Issue
    • Papers in Press
    • Abridged Standards of Care
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.